Cargando…
Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
Head and neck squamous cell carcinoma (HNSCC) has a high prevalence and is a major cause of cancer deaths in Taiwan. However, there is still no effective salvage therapy that prolongs the life expectancy of patients with recurrent/metastatic (R/M) HNSCC. Immune checkpoint therapy that targets the pr...
Autores principales: | Chen, Wen-Chun, Chu, Pen-Yuan, Lee, Yu-Ting, Lu, Wen-Bin, Liu, Chun-Yu, Chang, Peter Mu-Hsin, Yang, Muh-Hwa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392576/ https://www.ncbi.nlm.nih.gov/pubmed/29384959 http://dx.doi.org/10.1097/MD.0000000000009519 |
Ejemplares similares
-
Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
por: Chen, Tien-Hua, et al.
Publicado: (2022) -
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study
por: Chen, San-Chi, et al.
Publicado: (2016) -
Tumor-associated tissue eosinophilia promotes angiogenesis and metastasis in head and neck squamous cell carcinoma
por: Lee, Tsung-Lun, et al.
Publicado: (2022) -
PD-L1 expression is associated with p16(INK4A) expression in non-oropharyngeal head and neck squamous cell carcinoma
por: Chen, San-Chi, et al.
Publicado: (2018) -
Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
por: McCusker, Michael G, et al.
Publicado: (2020)